Condition
Postpartum Depression
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 26 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownGestational Diabetes and Perinatal Depression: an Intervention ProgramNCT05800509 · 2023-10-26
RECRUITINGRCT of At-Home tDCS for Depression in PregnancyNCT05097586 · 2021-11-08
RECRUITINGMaternal Mental Health TrialNCT04685148 · 2021-02-03
RECRUITINGFeasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression PreventionNCT06365645 · 2024-06-07
COMPLETEDPostpartum Video Education in High Risk PopulationsNCT06310720 · 2024-05-09
TERMINATEDA Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum DepressionNCT06285916 · 2024-03-28
COMPLETEDPostpartum Video EducationNCT05159726 · 2022-07-05
COMPLETEDThe Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum DepressionNCT04950868 · 2022-03-18
ACTIVE_NOT_RECRUITINGMothers and Babies Qatar (MB-Q): A Postpartum Depression InterventionNCT04442529 · 2021-05-01
UNKNOWNWillkommen Mutterglück: Online CBT for Pregnant and Postpartum Women With Depression and AnxietyNCT04183946 · 2020-06-01
UNKNOWNA Study of Pregnant and Postpartum Women With and Without Mood DisordersNCT03615794 · 2017-10-01
COMPLETEDA Study to Evaluate SAGE-217 in Participants With Severe Postpartum DepressionNCT02978326 · 2017-01-04
COMPLETEDA Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)NCT02942004 · 2016-08-01
COMPLETEDA Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)NCT02942017 · 2016-07-01
COMPLETEDEvaluate SAGE-547 in Female Participants With Severe Postpartum DepressionNCT02285504 · 2015-01-07
COMPLETEDThe Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 MonthsNCT02221895 · 2014-03-01
COMPLETEDIntegrated Chronotherapy for Perinatal DepressionNCT02053649 · 2014-01-01
COMPLETEDTask Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South AfricaNCT01977326 · 2013-10-01
COMPLETEDMommy-Baby Treatment for Perinatal DepressionNCT01744041 · 2012-11-01
COMPLETEDAripiprazole and Resistant Postpartum DepressionNCT01386086 · 2011-06-01
COMPLETEDNeuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for DepressionNCT02661789 · 2011-01-01
COMPLETEDPerinatal Depression Treatment in a Pediatric Setting- Pilot PhaseNCT00804739 · 2009-01-01
COMPLETEDPostpartum Depression: Transdermal Estradiol Versus SertralineNCT00744328 · 2008-08-01
TERMINATEDA Prospective Study of Postpartum Depression in Women With Major DepressionNCT01328613 · 2007-11-09
TERMINATEDDuloxetine for the Treatment of Postpartum DepressionNCT00617045 · 2007-07-01
WITHDRAWNLexapro in the Treatment of Patients With Postpartum DepressionNCT00277108 · 2004-02-01
COMPLETEDCommon interventions
PlaceboDRUG5SAGE-547 90 μg/kg/hDRUG2Video EducationOTHER2active tDCSDEVICE1App-based parenting educationBEHAVIORAL1aripiprazoleDRUG1basic counselling by lay-health workersBEHAVIORAL1Clips InterventionBEHAVIORAL1duloxetineDRUG1Dyadic Interpersonal PsychotherapyBEHAVIORAL1Enhanced Treatment as UsualOTHER1Enhanced usual careOTHER1Escitalopram (Lexapro)DRUG1Goserelin 3.6 mg implantDRUG1M.BappBEHAVIORAL1Mother-Infant Treatment TeamOTHER1Mothers and Babies (MB)BEHAVIORAL1NORA520 Dose 1DRUG1NORA520 Dose 2DRUG1Online Cognitive Behavioural TherapyBEHAVIORAL1PlaceboOTHER1Postpartum follow up 6-8wk after deliveryOTHER1Postpartum follow up appointment 2-3 weeks after deliveryOTHER1QuetiapineDRUG1SAGE 217 30 mg CapsulesDRUG1
Leading sponsors
Supernus Pharmaceuticals, Inc.
3
University of Rochester
2
Yale University
2
Biogen
1
Gitte Moos Knudsen
1
Johns Hopkins University
1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
1
Madigan Army Medical Center
1
National Institute on Aging (NIA)
1
National Taiwan University Hospital
1
Northwestern University
1
Rhode Island Hospital
1
Sidra Medicine
1
TWi Biotechnology, Inc.
1
University of Cape Town
1
Trial status mix
COMPLETED16
RECRUITING3
TERMINATED3
UNKNOWN2
ACTIVE_NOT_RECRUITING1
WITHDRAWN1
Phase mix
NA15
PHASE34
PHASE23
PHASE12
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.